FDA approves Lenvatinib for the treatment of thyroid cancer
https://www.cancercurepharmacy.com/BlogDetails.aspx?Title=FDA-approves-Lenvatinib-for-the-treatment-of-thyroid-cancer In early 2015, the US Food and Drug Administration or FDA approved Generic Lenvatinib / Brand Lenvima for treating patients diagnosed with thyroid cancer. It can be prescribed for treating metastatic differentiated (locally recurrent) thyroid cancer that has grown even after treatment therapy (radioactive iodine). Metastatic thyroid cancer is the most commonly diagnosed form of thyroid cancer. Over 56,500 new cases of metastatic differentiated thyroid cancer are estimated annually. However, the 5-year survival rate for patients of this cancer is close to 98%.
★
★
★
★
★
44 views • 3 slides
